Abstract
This review gives an overview of national registries that are currently in use for patients with multiple sclerosis (MS). The large-scale registries described herein include the Danish MS Registry, the Norwegian MS Registry, the Swedish MS Registry, the Italian MS Database Network, the North-American NARCOMS Registry, and the German MS Registry. These MS registries are extremely helpful for studying disease characteristics in large populations and monitoring the long-term outcome of disease-modifying therapies. Furthermore, an almost complete ascertainment of cases provides information on the provision of treatments, services and supplies within a given area that may be used to compare different levels of health care within and between these regions. In the long-term, MS registries monitor the health care situation of MS patients over time including the implementation of guidelines relating to care and treatment, measure the improvements that have taken place, and reveal shortages and/or misalignment in health care services. The information gathered herein is not only useful for the long-term follow-up of the individual patient, but also for society as a whole by increasing understanding of and knowledge about MS and allowing national authorities and relevant parties to make informed and relevant decisions about MS.
Similar content being viewed by others
References
Bronnum-Hansen H, Hansen T, Koch-Henriksen N, Stenager E (2006) Fatalaccidents among Danes with multiplesclerosis. Mult Scler 12:329–332
Butzkueven H, Chapman J, Cristiano E,Grand’Maison F, Hoffmann M, IzquierdoG, Jolley D, Kappos L, Leist T,Pöhlau D, Rivera V, Trojano M, VerheulF, Malkowski JP (2006) MSBase: aninternational, online registry andplatform for collaborative outcomesresearch in multiple sclerosis. MultScler 12:769–774
Flachenecker P, Hartung HP (1996)EDMUS – eine europäische Datenbankfür multiple Sklerose. Eine kurze Vorstellungbereits laufender und nochgeplanter multizentrischer Studien imRahmen der “Europäischen konzertiertenAktion für multiple Sklerose”.Nervenarzt 67:277–282
Flachenecker P, Stuke K, Elias W,Freidel M, Haas J, Pitschnau-Michel D,Schimrigk S, Zettl UK, Rieckmann P(2008) Multiple-Sklerose-Register inDeutschland. Ausweitung des Projektes2005/2006. Dt Ärztebl 105:113–119
Flachenecker P, Zettl UK, Götze U,Haas J, Schimrigk S, Elias W, Pette M,Eulitz M, Hennig M, Bertram J, HollweckR, Neiss A, Daumer M, Pitschnau-Michel D, Rieckmann P (2005) MSRegister in Deutschland – Design underste Ergebnisse der Pilotphase.Nervenarzt 76:967–975
Flachenecker P, Zettl UK, Götze U,Stuke K, Elias W, Eulitz M, Haas J, PetteM, Pitschnau-Michel D, Schimrigk S,Rieckmann P (2007) MS-Register inDeutschland: abschliessende Ergebnisseder Pilotphase. Neurol Rehabil13:193–200
Kobelt G, Berg J, Lindgren P, Jonsson B(2006) Costs and quality of life inmultiple sclerosis in Europe: methodof assessment and analysis. Eur JHealth Econ 7(Suppl 2):S5–S13
Koch-Henriksen N, Hyllested K (1988)Epidemiology of multiple sclerosis:incidence and prevalence rates inDenmark 1948–64 based on the DanishMultiple Sclerosis Registry. Acta NeurolScand 78:369–380
Koch-Henriksen N, Rasmussen S,Stenager E, Madsen M (2001) TheDanish Multiple Sclerosis Registry.History, data collection and validity.Dan Med Bull 48:91–94
Landtblom AM, Stawiarz L, Ahlgren C,Andersen O, Callander M, Boström I,Severinson G, Hillert J (2007) TheNational Swedish MS Register detectsan unexpectedly high prevalence inSweden. Mult Scler 13(Suppl 2):104
Lo AC, Hadjimichael O, Vollmer TL(2005) Treatment patterns of multiplesclerosis patients: a comparison ofveterans and non-veterans using theNARCOMS registry. Mult Scler 11:33–40
Marrie RA, Cutter G, Tyry T, CampagnoloD, Vollmer T (2007) Validation ofthe NARCOMS registry: diagnosis.Mult Scler 13:770–775
Marrie RA, Cutter G, Tyry T, HadjimichaelO, Campagnolo D, Vollmer T(2005) Changes in the ascertainmentof multiple sclerosis. Neurology 65:1066–1070
Multiple Sklerose Therapie KonsensusGruppe, Rieckmann P (2006) ImmunmodulatorischeStufentherapie derMultiplen Sklerose: Update September2006. Nervenarzt 77:1506–1518
Myhr KM, Grytten N, Aarseth JH,Nyland H (2006) The NorwegianMultiple Sclerosis National CompetenceCentre and National MultipleSclerosis registry – a resource for clinicalpractice and research. Acta NeurolScand (Suppl) 183:37–40
National Multiple Sclerosis Society(2008) Support establishing a nationalmultiple sclerosis registry. wwwnationalmssociety org/downloadaspx?id=1031
Schwartz CE, Vollmer T, Lee H (1999)Reliability and validity of two self-reportmeasures of impairment anddisability for MS. North AmericanResearch Consortium on MultipleSclerosis Outcomes Study Group.Neurology 52:63–70
Sorensen PS, Koch-Henriksen N,Ravnborg M, Frederiksen JL, Jensen K,Heltberg A, Schaldemose H, Deth S,Kristensen O, Worm M, Stenager E,Hansen HJ, Sivertsen B, Torring J(2006) Immunomodulatory treatmentof multiple sclerosis in denmark: aprospective nationwide survey. MultScler 12:253–264
Sorensen TL, Frederiksen JL,Bronnum-Hansen H, Petersen HC(1999) Optic neuritis as onset manifestationof multiple sclerosis: a nationwide,long-term survey. Neurology53:473–478
Stuke K, Flachenecker P, Zettl U, EliasW, Freidel M, Haas J, Pitschnau-MichelD, Schimrigk S, Rieckmann P (2008)MS Register in Germany: update 2007.J Neurol 255(Suppl 2):II81
Trojano M (2004) Can databasingoptimise patient care? J Neurol 251(Suppl 5):v79–v82
Trojano M, Paolicelli D, Lepore V,Fuiani A, Di ME, Pellegrini F, Russo P,Livrea P, Comi G (2006) Italian MultipleSclerosis Database Network. NeurolSci 27(Suppl 5):S358–S361
Trojano M, Russo P, Fuiani A, PaolicelliD, Di ME, Granieri E, Rosati G, SavettieriG, Comi G, Livrea P (2006) TheItalian Multiple Sclerosis DatabaseNetwork (MSDN): the risk of worseningaccording to IFNbeta exposure inmultiple sclerosis. Mult Scler 12:578–585
Weinshenker BG (1999) Databases inMS research: pitfalls and promises.Mult Scler 5:206–211
Wingerchuk DM, Noseworthy JH(2002) Randomized controlled trials toassess therapies for multiple sclerosis.Neurology 58(Suppl 4):S40–S48
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of interest Peter Flachenecker has received speaker’s fees and honoraria from Bayer-Schering, Biogen idec, Sanofi-Aventis, Merck-Serono, and Novartis, and research grants from Bayer-Schering, Sanofi-Aventis and Merck-Serono. None of these relationships resulted in a possible conflict of interest. Kristin Stuke has no conflict of interest to declare.
Rights and permissions
About this article
Cite this article
Flachenecker, P., Stuke, K. National MS registries. J Neurol 255 (Suppl 6), 102–108 (2008). https://doi.org/10.1007/s00415-008-6019-5
Issue Date:
DOI: https://doi.org/10.1007/s00415-008-6019-5